Meritain Health policies

Search Meritain Health's public medical, payment and drug policies by CPT or HCPCS code, keyword or policy number, with links to the payer's own documents. Links open the payer's own document; check its current version before relying on it.

54 policies name 38240, those listing the fewest codes first. A policy that names a code may also list it as excluded.

Meritain Health policies
PolicyDetailsCodesSource
0773-Transplant Immune Cell Function Assays0773 · Commercial5Original policy ↗
Hematopoietic Cell Transplantation for Waldenstrom Macroglobulinemia0833 · Commercial5Original policy ↗
0115-Varicella and Herpes Zoster Vaccines0115 · Commercial6Original policy ↗
0241-Extracorporeal Photochemotherapy (Photopheresis)0241 · Commercial6Original policy ↗
0830-Hematopoietic Cell Transplantation for Primary Immunodeficiency Disorders0830 · Commercial6Original policy ↗
0851-Palifermin (Kepivance)0851 · Commercial7Original policy ↗
Hematopoietic Cell Transplantation for Testicular Cancer0617 · Commercial8Original policy ↗
0048-Hepatitis A Vaccine0048 · Commercial9Original policy ↗
0838-Stem Cell Transplantation for Myelofibrosis0838 · Commercial9Original policy ↗
1032-Omidubicel-onlv (Omisirge)1032 · Commercial9Original policy ↗
Hematopoietic Cell Transplantation for Ovarian Cancer0635 · Commercial9Original policy ↗
0674-Hematopoietic Cell Transplantation for Chronic Myelogenous Leukemia0674 · Commercial11Original policy ↗
Autologous Skeletal Myoblast/Mononuclear Bone Marrow Cell Transplantation0599 · Commercial12Original policy ↗
0871-Hematopoietic Cell Transplantation for Inherited Metabolic Disorders and Genetic Diseases0871 · Commercial13Original policy ↗
0836-Hematopoietic Cell Transplantation for Myelodysplastic Syndrome0836 · Commercial14Original policy ↗
0779-Plerixafor0779 · Commercial15Original policy ↗
0811-Hematopoietic Cell Transplantation for Solid Tumors in Adults0811 · Commercial15Original policy ↗
ADAMTS13 Assay for Thrombotic Thrombocytopenic Purpura (TTP)0780 · Commercial15Original policy ↗
Hematopoietic Cell Transplantation for Non-Hodgkin's Lymphoma0494 · Commercial16Original policy ↗
Hematopoietic Cell Transplantation for Selected Leukemias0640 · Commercial17Original policy ↗
Betibeglogene Autotemcel (Zynteglo)1016 · Commercial18Original policy ↗
Hematopoietic Cell Transplantation for Autoimmune Diseases and Miscellaneous Indications0606 · Commercial19Original policy ↗
Non-myeloablative Hematopoietic Cell Transplantation (Mini-Allograft / Reduced Intensity Conditioning Transplant)0634 · Commercial19Original policy ↗
Hematopoietic Cell Transplantation for Multiple Myeloma0497 · Commercial21Original policy ↗
1097-Etuvetidigene Autotemcel (Waskyra)1097 · Commercial22Original policy ↗
Hematopoietic Cell Transplantation for Hodgkin's Disease0495 · Commercial23Original policy ↗
1099-Narsoplimab-wuug (Yartemlea)1099 · Commercial25Original policy ↗
Hematopoietic Cell Transplantation for Selected Childhood Solid Tumors0496 · Commercial25Original policy ↗
YAG Laser in Ophthalmology and Other Selected Indications0354 · Commercial26Original policy ↗
Hematopoietic Cell Transplantation for Thalassemia Major and Sickle Cell Anemia0626 · Commercial27Original policy ↗
Stem Cells for Hematopoietic Cell Transplant0190 · Commercial29Original policy ↗
0195-Erythropoesis Stimulating Agents0195 · Commercial32Original policy ↗
Pegzilarginase-nbln (Loargys)1101 · Commercial35Original policy ↗
Dry Eyes0457 · Commercial36Original policy ↗
Hematopoietic Cell Transplantation for Aplastic Anemia and other Bone Marrow Failure Syndromes0627 · Commercial36Original policy ↗
0544-Immune Globulins for Post-exposure Prophylaxis0544 · Commercial41Original policy ↗
1017-Elivaldogene Autotemcel (Skysona)1017 · Commercial44Original policy ↗
0765-Age-related Macular Degeneration0765 · Commercial47Original policy ↗
0823-Brentuximab Vedotin (Adcetris)0823 · Commercial47Original policy ↗
1102-Marnetegragene Autotemcel (Kresladi)1102 · Commercial48Original policy ↗
0812-Hypoxic Ischemic Encephalopathy0812 · Commercial53Original policy ↗
Hypertrophic Scars and Keloids0389 · Commercial56Original policy ↗
Huntington's Disease0614 · Commercial60Original policy ↗
Fecal Incontinence0611 · Commercial62Original policy ↗
Epilepsy Surgery0394 · Commercial84Original policy ↗
Bone and Tendon Graft Substitutes and Adjuncts0411 · Commercial86Original policy ↗
Hematopoietic Colony-Stimulating Factors (CSFs)0055 · Commercial91Original policy ↗
0788-Alzheimer's Disease: Experimental, Investigational, or Unproven Treatment0788 · Commercial95Original policy ↗
Parenteral Immunoglobulins0206 · Commercial107Original policy ↗
Erectile Dysfunction and Peyronie's Disease0007 · Commercial111Original policy ↗

Back to Meritain Health

Disclaimer

The information provided on this page is for general informational purposes only and does not constitute billing, coding, or reimbursement advice. Nothing on this page should be relied upon as a substitute for clinician assessment, professional billing guidance, or as a definitive statement of any payor's billing requirements or policies.

Payor agreements, fee schedules, and billing policies vary and are subject to change. Before submitting any claims related to maternity care services, including claims affected by the 2027 CPT code revisions, please consult the applicable payor agreements, coverage policies, and billing guidelines to confirm current requirements for their specific payor contracts.

Substrate makes no representation or warranty regarding the accuracy, completeness, or timeliness of the payor-specific information presented here. Providers are solely responsible for ensuring that all claims are submitted in accordance with applicable payor requirements, and Substrate assumes no liability for claim denials, underpayments, or other adverse outcomes arising from reliance on this information.